Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II rituximab + pembrolizumab in relapsed/refractory Waldenström's macroglobulinaemia
2018-001767-23Phase 2Unknown
- Sponsor
- University College London
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and rituximab in Waldenström macroglobulinemia (WM), sponsored by University College London. Primary endpoint: Overall response rate at 24 weeks. Status: unknown.
02
Drugs
pembrolizumabrituximab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2018-001767-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001767-23.